Wellesta | Value Added Partner for Healthcare

Company Overview

As a focused Healthcare company we are open to provide tailor made marketing and promotion solutions..

Policy & Business Conduct

As a focused Healthcare company we are open to provide tailor made marketing and promotion solutions..

As a focused Healthcare company we are open to provide tailor made marketing and promotion solutions..

Quality Product Supply

As a focused Healthcare company we are open to provide tailor made marketing and promotion solutions..

Healthcare Professionals

As a focused Healthcare company we are open to provide tailor made marketing and promotion solutions..

Announcements

All

HQ, Singapore

Indonesia

India

Singapore

Malaysia

Philippines

Bangladesh

Europe

View By:

We are pleased to announce the appointment of Anne Juliah as Regional Head, DTC for Wellesta with effect from 15th Jul, 2024

- Effective from 15th Jul, 2024

Ms. Anne Juliah has been appointed as Regional Head, DTC with effect from July 15 th , 2024.She is a seasoned commercial leader with 20+ years of diverse experiences in Multi-national pharmaceutical, Healthcare and FMCG companies. Prior to joining Wellesta, Anne was the APAC Regional Head of Retail Sales at Abbott Laboratories.

Appointments, HQ Singapore

We are pleased to announce our collaboration with BrainCapture for BC-1, the first global point-of-care EEG device that makes neurodiagnostics accessible to all.

- Effective from: 24th June, 2024

Wellesta and BrainCapture, a Medical Technology company based in Denmark, have signed a sales, marketing & distribution agreement for BC-1 to commercialise the device in SEA markets, followed by India and other ASEAN countries.

Business, HQ Singapore

We are pleased to announce the appointment of Dimple Lalwani as Head of Finance for Wellesta Group with effect from 1st June 2024

- Effective from 1st June 2024

Dimple Lalwani has been appointed as Head of Finance for Wellesta Group with effect from 1st June, 2024. She is a seasoned finance leader with over 20 years of experience in FP&A, Controllership, and Audits, with a proven track record of building high-performing teams.

Appointments, HQ Singapore

We are pleased to announce our strategic partnership with Melody International, Japan for commercialising Wearable Fetal Monitor iCTG in Asian countries.

- Effective from 22nd June, 2024

Wellesta and Melody International, Japan have signed an agreement for sales, marketing and distribution of Wearable Fetal Monitor iCTG for Asian markets. This is a cloud-type mobile wireless fetal monitor which is already in use in Japan for the past few years, can be used Anywhere at Any time providing smarter way to check maternal & fetal conditions.

Business, HQ Singapore

We are pleased to announce the partnership with Butterfly Network, Inc. to market and distribute Point-Of-Care Ultrasound (POCUS) Butterfly Human and Butterfly Vet in South-East Asian countries.

- Effective from 12th Mar, 2024

Wellesta, a healthcare company headquartered in Singapore, unveils the partnership with Butterfly Network Inc., a medical devices manufacturer based in USA, for sales, marketing & distribution of its Point-Of-Care Ultrasound Butterfly Human and Butterfly Vet, thereby adding additional products in their MedTech vertical for the South-east Asian market.

Business, HQ Singapore

We are pleased to announce the appointment of Dr. Beat Sumegi as Regional Head/Managing Director of the Wellesta Group for Europe Business

- Effective from 1st Jun, 2024

Dr. Beat Sumegi has been appointed as Regional Head/Managing Director of Wellesta Group for Europe business. Prior to joining Wellesta, he was the Global Head for Medical Excellence & Operations for Galderma S.A, Switzerland.

Appointments, HQ Singapore , Europe

We are pleased to announce the collaboration with Escala Medical for the launch of Innovative product for pelvic prolapse in women in Asia.

- Effective from 12th May, 2024

It brings us immense pleasure to announce our collaboration for the launch of an innovative product developed by Escala Medical, led by Edit Goldberg to address significant need in women's health. The product we are introducing offers a solution for millions of women who suffer from pelvic prolapse.

Business, HQ Singapore

Wellesta acquires minority shares in Cureleads - UAE, our Partner in MENA

- Effective from 13th Dec, 2023

We are excited to announce that Wellesta has acquired minority shares in Cureleads, a fast-growing BioPharma company in MENA. Through this investment, we aim to strengthen our collaboration and march towards accomplishing our objectives in MENA region.

Business, HQ Singapore

We are pleased to announce that IntelliMed Healthcare Solutions that offers Medical Affairs solutions in Healthcare Industry, is now a Wellesta Group Company

- Effective from 19th Sept, 2023

IntelliMed Healthcare Solutions is a Scientific Partner that collaborates with Healthcare companies to provide innovative and practical solutions in the area of Medical Affairs, Medical Writing, Real World Evidence generation in areas of Pharmaceuticals, Medical devices and Nutraceuticals.

Business, HQ Singapore

19th Sept, 2023

We are pleased to announce the appointment of Mr. Venkatesan Karaiyalan as Head of Finance for India Business and Financial Process Excellence Lead for Wellesta Group of Companies

- Effective from 11th Jan, 2024

Mr. Venkatesan Karaiyalan has been appointed as Head of Finance for Wellesta Healthcare Pvt. Ltd., India and Financial Process Excellence Lead for Wellesta Group in areas like enrichment of Technical Accounting Principles and System Lead.

Appointments, HQ Singapore, India

We are pleased to announce the appointment of Mr. Ashish Srivastava as Country Head for India business & to Wellesta India BOD.

- Effective from 11th Dec, 2023

Mr. Ashish Srivastava has been appointed as Country Head for India business and also to the Wellesta India Board of Directors. Ashish is a seasoned player with extensive experience of 27 years in building brands, turning around & scaling up businesses.

Appointments, India

We are pleased to announce our strategic partnership with BioCheetah for commercializing VECanDx™ ELISA test for early detection of bladder cancer.

- Effective from 29th Nov 2023

Wellesta and BioCheetah have signed an agreement whereby Wellesta will be commercializing BioCheetah’s unique, patented and biomarker-based test kit, VECanDx™ ELISA test for early detection of bladder cancer.

Business, HQ Singapore

We are pleased to announce Advanced Chemicals Industries (ACI) Pharma as our strategic partner for Bangladesh market.

- Effective from 27th Oct 2023

Wellesta Holdings and Advanced Chemicals Industries (ACI) Pharma have entered into sales and marketing agreement for FathomX, BioCheetah, Butterfly & SKIIP for Bangladesh market.

Business, HQ Singapore, Bangladesh

We are excited to announce Ancom Truelife as our distribution partner in Malaysia for Fx Mammo, a new Artificial Intelligence (AI) powered breast cancer detection software

- Effective from 20th Oct 2023

Wellesta Holdings Pte Ltd announces Ancom Truelife, a healthcare solution provider in Malaysia, as its Distribution partner for selling and marketing Fx Mammo, an AI-based breast cancer detection software, in the government healthcare institutions in Malaysia.

Business, Malaysia

We are pleased to announce the appointment of Ms. Serene Ng as Regional Project Manager, Pharma for Wellesta

- Effective from 17th July, 2023

We are pleased to announce the appointment of Ms. Serene Ng as Regional Project Manager, Pharma for Wellesta w.e.f. 17th July, 2023. Prior to joining Wellesta, Ms. Serene worked as Regional Manager at Medochemie responsible for SEA, Hong Kong, Macau and Taiwan’s overall business. She is a seasoned commercial leader with over 20 years of experience within the pharmaceutical industry.

Appointments, HQ Singapore

17th July, 2023

We are pleased to announce the appointment of Ms. Anisha Ramkorun as Accounting Manager for Wellesta.

- Effective from 30th June, 2023

We are pleased to announce the appointment of Ms. Anisha Ramkorun as Accounting Manager for Wellesta w.e.f. 30th June, 2023. Prior to joining Wellesta, Ms. Anisha worked as Senior Finance Analyst at Johnson & Johnson.She has an experience of 12 years in the field of Accounts and Finance with strong business acumen and GAAP knowledge.

Appointments, HQ Singapore

30th June, 2023

We are pleased to announce the appointment of Ms. Soyoka Yoshimi as Project Manager, Pharmaceuticals for Wellesta.

- Effective from 12th June, 2023

We are pleased to announce the appointment of Ms. Soyoka Yoshimi as Project Manager - Pharmaceuticals, for Wellesta w.e.f. 12 th June, 2023. Prior to joining Wellesta, Ms. Soyoka worked as Project Manager, Global Healthcare Solution Department, Healthcare Business Unit at Mitsui & Co., Ltd., Tokyo Japan.

Appointments, HQ Singapore

12th June, 2023

Wellesta announces Mitsui & Co., Ltd and Japan Bank for International Cooperation (JBIC) as Series B Investors in the company. This Investment round will help Wellesta for its strategic growth initiatives & geographical expansion.

- Effective from 6th April 2023

Wellesta, today announced a joint investment in the company from Mitsui & Co., Ltd and Japan Bank for International Cooperation, known as JBIC. This strategic move will support our business growth initiatives; better support our Principals; wider and deeper access of products for our Patients.

Business, HQ Singapore

We are pleased to announce the appointment of Ms. Pearleen Tan Ching Yen as Regional Marketing Head, DTC for Wellesta w.e.f. 17th April 2023.

- Effective from 17th April 2023

We are pleased to announce the appointment of Ms. Pearleen Tan as Regional Marketing Head Manager – Direct to Consumer, for Wellesta w.e.f. 17 th April 2023. Prior to joining Wellesta, Ms. Pearleen Tan worked as Head of Marketing for India & SEA at Hillrom, Singapore which is now a part of Baxter. She is a true Marketing leader with over 20 years of experience and global exposure in Marketing and Distributor Sales Management.

Appointments, HQ Singapore

24th March 2023

We are pleased to announce the appointment of Ms. Chang Shen Yun as Regional IT Manager for Wellesta w.e.f. 20th February 2023.

- Effective from 20th Feb 2023

We are pleased to announce the appointment of Ms. Chang Shen Yun as Regional IT Manager for Wellesta w.e.f. 20th February 2023. Prior to joining Wellesta, Ms. Shen worked with Robert Bosch Sdn Bhd, Malaysia as an IT Manager & Head of Department. Her IT experience spans over 24 years in IT industry with specialization in IT infrastructure & IT operations.

Appointments, HQ Singapore

Abdul Latif Jameel Health and Wellesta announce collaboration to bring the innovative Butterfly iQ+^TM Point-Of-Care Ultrasound (POCUS) solution to serve the medical imaging needs of over 1.3 billion people across India

- Effective from 1st October 2022.

Abdul Latif Jameel Health part of international diversified family business Abdul Latif Jameel, and Wellesta Holdings Pte. Ltd., a Singapore headquartered company providing marketing and commercialization support to the healthcare sector in South East Asia, India & partnering in MENA, today announced an important new agreement for the marketing and distribution of the Butterfly iQ+^TM point-of-care ultrasound device in The Republic of India.

Business, HQ Singapore, India

We are pleased to announce the appointment of Ms. Prinka Mittal as Business Development & Marketing Manager for Wellesta Holdings, Singapore & her appointment is w.e.f. 16th August 2022.

- Effective from 16th August 2022.

We are pleased to announce the appointment of Ms. Prinka Mittal as Business Development & Marketing Manager for Wellesta Holdings, Singapore & her appointment is w.e.f. 16th August 2022. Prior to joining Wellesta, Ms. Prinka worked with Naari Pharma (a Tenshi Group of Lifesciences’ company) as Senior Manager, Business Development for other regulated markets, emerging markets and global strategic accounts. Her career spans over 10 years of comprehensive experience in International Business Development for regulated markets like Europe, Australia & NZ, Canada and emerging markets.

Appointments, HQ Singapore

We are pleased to announce the appointment of Mr. Vishwajit Kamat as Chief Commercial Officer for Wellesta India and Gynaec Business Lead for Wellesta Group of Companies.

- Effective from 20th June 2022

Mr. Vishwajit Kamat has been appointed as Chief Commercial Officer for Wellesta India and Gynaec Business Lead for Wellesta Group of Companies with effect from June 20th 2022.

Appointments, India

Wellesta Holdings Pte Ltd is pleased to broaden collaboration with Altamira Therapeutics to market and distribute Bentrio in two additional markets.

Wellesta Holdings Pte Ltd and Altamira Therapeutics Ltd have broaden their agreement for marketing and distribution of Bentrio™ by including two attractive new markets. In addition to India, Indonesia, Malaysia, Singapore, Taiwan and Vietnam, Wellesta will also start promoting and selling Bentrio™ in Philippines & Morocco, upon registration in these two countries.

Business, HQ, Singapore

11th February 2022

Wellesta Holdings Pte Ltd is pleased to announce a collaboration with Altamira Therapeutics to market and distribute Bentrio in Six Key Asian Markets

Wellesta Holdings Pte Ltd and Altamira Therapeutics Ltd. have signed a letter of understanding (“LOU”) for the marketing and distribution of Bentrio™ in India, Indonesia, Malaysia, Singapore, Taiwan and Vietnam. Bentrio™ is a nasal spray for protection against airborne viruses and allergens. Wellesta will register Bentrio™ in the respective countries and start promoting and selling the product in those markets.

Business, HQ, Singapore

2nd November 2021

Wellesta Holdings Pte. Ltd. is pleased & excited to announce an update on business development for the Philippines: Wellesta will enter Philippine market through the purchase of a majority stake in Buergli Pharma Inc.

- Effective from 1st November 2021

Buergli Pharma Inc has been operating in Philippines as an established Healthcare company for 15 years and is also committed to providing affordable quality medicine and unique products to further develop and improve healthcare outcomes in the Philippines and Southeast Asia. With the new combined business, we assure more employee development opportunities and a larger and faster growing business for our current employees & partners in Philippines.

Business, Philippines

2nd November 2021

We are pleased to announce the appointment of Ms. Carla Aquino as Country Manager for Philippines for Wellesta w.e.f 18th October, 2021.

- Effective from 18th October 2021

Prior to joining Wellesta, Carla was with AstraZeneca Philippines as Business Unit Head and Head for the Oncology Business Unit. She has extensive experience with almost 19 years in the pharmaceutical industry, both in consumer and ethical businesses, handling multiple therapeutic areas such as Cardiovascular, Diabetes, Neurology, Psychiatry, Respiratory and Oncology.

Appointments, Philippines

19th October 2021

Wellesta & Rubicon Research announce partnership to launch Nicotine Mini Lozenges in Asia.

Rubicon Research Pvt Ltd and Wellesta Holdings Pte. Ltd enter into a licensing and supply partnership to launch a highly effective nicotine lozenge that helps smokers to quit smoking. This smoking cessation product helps smokers successfully wean off their nicotine addiction in 12 weeks and helps them embark on a healthier journey of living cigarette-free.

Business, Singapore

We are pleased to announce the appointment of Ms. Sally Kuah as Country Manager for Malaysia for our Pharma business w.e.f 1st July, 2021.

- Effective from 1st July 2021

Ms. Sally Kuah has been appointed as Country Manager for Wellesta Healthcare Sdn Bhd, Malaysia. This legal entity will focus on Pharmaceutical Business of Wellesta in Malaysia. Sally will join us from 1st July 2021. Her last position was the Business Unit Director for MSD Malaysia, Singapore and Brunei. She has extensive experience with 20 years in pharmaceutical industry in multiple therapeutic areas such as Vaccine, Neurology, Psychiatry, Diabetes, Ophthalmology and Cardiovascular.

Appointments, Malaysia

We are pleased to announce the collaboration with Escala Medical for the launch of Innovative product for pelvic prolapse in women in Asia.

- Effective from 12 May 2024

It brings us immense pleasure to announce our collaboration for the launch of an innovative product developed by Escala Medical, led by Edit Goldberg to address significant need in women's health. The product we are introducing offers a solution for millions of women who suffer from pelvic prolapse.

Business, HQ Singapore

We are pleased to announce a Supply and Licensing collaboration with SGN Nanopharma, Inc. and Cureleads to launch Nanotherapeutics Optha in SEA and MENA.

- Effective from 27 Apr 2021

This collaboration aims to establish a series of nanotherapeutics technology for patients with dry eye diseases. The first product to be launched will be in the Ophthalmic category.

Business, Singapore

We are pleased to announce an update on business development for the Malaysian market: Wellesta group in Malaysia will be merging business with the TrueLife group in Malaysia.

- Effective from 6th Jan 2021

Wellesta group in Malaysia will be merging business with the TrueLife group of Malaysia. The nutraceutical business will be done by Wellesta TrueLife Sdn. Bhd. and the pharma business will be done by Wellesta Healthcare Sdn. Bhd.

Business, Malaysia

We are pleased to announce the Joint Venture of Naari & Wellesta for Singapore as NaariEsta Pte Ltd.

- Effective from 27th Nov 2020

Naari Pte Ltd & Wellesta Holdings Pte Ltd are pleased to announce its joint venture for Singapore as NaariEsta Pte Ltd. Naari will be investing 65% and Wellesta would invest 35% in the joint venture. This will be a vertically integrated, women’s health focused company: NaariEsta Pte Ltd, operating in Singapore and Brunei markets.

Business, Singapore

We are pleased to announce the appointment of Mr. Ravinder Kumar Sagar as CEO and Country Head for India with effect from Feb 1st 2021.

- Effective from 1st Feb 2021

Mr. Ravinder Kumar Sagar has been appointed as CEO and Country Head of India with effect from Feb 1st 2021. Mr. Sagar is a seasoned business leader with 39 years of experience, and an ambitious visionary who believes in looking at problems as opportunities. He was previously associated with Novartis for over three decades.

Appointments, India

We are pleased to announce the appointment of Dr. Beat Sumegi as Regional Head/Managing Director of the Wellesta Group for Europe Business

- Effective from 1st Jun 2024

Dr. Beat Sumegi has been appointed as Regional Head/Managing Director of Wellesta Group for Europe business. Prior to joining Wellesta, he was the Global Head for Medical Excellence & Operations for Galderma S.A, Switzerland.

Appointments, HQ Singapore, Europe

We are pleased to announce our Strategic Business Partnership for Middle East & North Africa with Cureleads, a company headquartered in Dubai & Beirut.

- Effective from 9 Sep 2020

We are pleased to announce the collaboration of Wellesta and Cureleads. Wellesta is a company headquartered in Singapore and support Healthcare companies to expand their reach of products for larger access to patients & brand building by way of offering sales, marketing & distribution. It also helps smaller MNC’s & Biotech companies as launch pad for their products to be launched in Asia Pacific.

Business, Singapore

We are pleased to announce our Strategic Business Alliance in India with Parazelsus through its subsidiary company Wellesta Healthcare Pvt. Ltd, India.

- Effective from July, 2020

Wellesta Holdings Pte. Ltd is pleased to announce strategic alliance in India with Parazelsus through its subsidiary company in India, Wellesta Healthcare Pvt. Ltd. Parazelsus is an MNC company founded by Peter Zuellig in 2007 and operates in multiple countries including India, specializing in Distribution & Logistics. The Company is led by Markus Haefeli as Managing Director. Parazelsus India with its focus on Distribution and Logistics in the Healthcare sector, decided to partner with Wellesta in India for its CSO & Sales and Marketing business.

Business, India

We are pleased to announce the appointment of Mr. Yohannes Sinaga as Country Manager, PT Wellesta CPI Indonesia.

- Effective from 1st May 2020

Mr. Yohannes Sinaga has been appointed as the Country Manager for PT Wellesta CPI Indonesia, effective from 1st May 2020. His last position was Chief Marketing Officer for AstraZeneca Indonesia. He has extensive experience with 15 years in pharmaceutical industry.

Appointments, Indonesia

We are pleased to announce the appointment of Mr. Paul Lim as Country Head for Singapore and OTC Lead for Singapore, Malaysia and Indonesia.

- Effective from 1st Mar 2020

Mr. Paul Lim has been appointed as Country Head for Singapore and OTC Lead for Singapore, Malaysia and Indonesia with effect from 1st March, 2020. Mr. Lim previously worked at Church & Dwight where he launched and achieved market leadership in numerous countries in the Nasal care and VMS categories as OTC Lead - Asia Pacific.

Appointments, Singapore

We are pleased to announce the appointment of Mr. Partha Dutt as Director, Marketing & New Product Strategy for India business.

- Effective from 1st Mar 2020

Mr. Partha Dutt has been appointed as Director, Marketing & New Product Strategy for Wellesta Healthcare Pvt. Ltd with effect from March, 2020. Mr. Dutt is a competent professional with over 22 years of experience in Consumer Healthcare, OTC and FMCG (Health & Wellness). In his previous role as CEO of Nutrite Healthcare, he was responsible for setting up the nutraceutical business from scratch.

Appointments, India

We are pleased to announce the appointment of Mr. Sharad Virmani as Director, Partner Business for Wellesta Healthcare Pvt. Ltd.

- Effective from 1st Feb 2020

Mr. Sharad Virmani has been appointed as Director, Partner Business for Wellesta Healthcare Pvt. Ltd with effect from 1st February, 2020. Mr. Virmani is a very well-rounded professional with over 35 years of experience in Pharma, Capital Equipment, Medical Devices, Diagnostics, Surgical & Healthcare in MNC & Indian Companies.

Appointments, India

We are pleased to announce the appointment of Mr. Dinesh Nair as Director, Supply Chain for India Business.

- Effective from 1st Dec 2019

Mr. Dinesh Nair has been appointed as Director, Supply Chain of our Indian Business with effect from 1st December, 2019. Mr. Nair is a seasoned business leader with over 35 years of experience in Pharmaceutical, OTC, Medical Nutrition & Food industry locally & Internationally. He was previously Managing Partner at Integratos India LLP, India.

Appointments, India

We are pleased to announce the appointment of Mr. Kamal Anand as Director, Sales for Wellesta Healthcare Pvt. Ltd, India.

- Effective from 1st Dec 2019

Mr. Kamal Anand has been appointed Director, Sales for India business with effect from 1st December, 2019. Mr. Anand is a competent professional with over 35 years of experience in Strategic Planning, Sales & Marketing and Business Development.

Appointments, India

We are pleased to announce our partnership in Indonesia by acquiring majority of shares & management control of PT Citra Pharma Indonesia.

- Acquired from 1st Dec 2019

We are pleased to announce our partnership in Indonesia by acquiring majority of shares & management control of PT Citra Pharma Indonesia from current shareholders. It will now operate under the new name PT Wellesta CPI Healthcare and will be based from Jakarta. PT Citra Pharma Indonesia is in successful operations for last 12-years and have been partner with MNC players in Pharma and Healthcare sector in the Indonesian market.

Business, Indonesia